Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832612 | 1.00 | CASR (0.50) | CASRSMN1; SMN2GAAUSP2LMNA | |
| SCHEMBL26105278 | 0.91 | CASR (0.50) | CASRSMN1; SMN2GAAUSP2LMNA | |
| SCHEMBL29832081 | 0.91 | CASR (0.50) | CASRSMN1; SMN2GAAUSP2LMNA | |
| SCHEMBL29832214 | 0.88 | TLR8 (0.45) | CASRSMN1; SMN2GAAUSP2LMNA | |
| SCHEMBL26107500 | 0.88 | TLR8 (0.45) | CASRSMN1; SMN2GAAUSP2LMNA | |
| SCHEMBL26491602 | 0.84 | CASR (0.53) | CASRSMN1; SMN2GAATLR8 | |
| SCHEMBL26109537 | 0.82 | CASR (0.52) | CASRSMN1; SMN2GAATLR8CNR2 | |
| SCHEMBL29832873 | 0.82 | CASR (0.52) | CASRSMN1; SMN2GAATLR8CNR2 | |
| SCHEMBL26487228 | 0.82 | CASR (0.43) | CASRSMN1; SMN2GAAUSP2LMNA | |
| SCHEMBL26492004 | 0.81 | CASR (0.61) | CASRSMN1; SMN2GAALMNATLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199777-A1 | AMINO-BENZIMIDAZOLE CATALYSTS FOR THE PREPARATION OF POLYOLEFINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4298136-A1 | AMINO-BENZIMIDAZOLE CATALYSTS FOR THE PREPARATION OF POLYOLEFINS | Dow Global Technologies LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022183008-A9 | AMINO-BENZIMIDAZOLE CATALYSTS FOR THE PREPARATION OF POLYOLEFINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2022183008-A9 | AMINO-BENZIMIDAZOLE CATALYSTS FOR THE PREPARATION OF POLYOLEFINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199777-A1 | AMINO-BENZIMIDAZOLE CATALYSTS FOR THE PREPARATION OF POLYOLEFINS | IL4I1, BCAT1, PARG | CASR 4678/4885SMN1; SMN2 3475/4885GAA 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.